E-cigarettes popularity forces firms to review policies

November 11, 2013

ecigar

When John Castellano feels like a smoke, he simply heads to the break room at Kraft Foods’s factory in Garland, Texas.

The technician has been able to indulge his habit in common areas at work since he started using electronic cigarettes, which emit vapor rather than smoke.

E-cigarettes are “very liberating,” said Castellano, 39, who used to join the other cigarette addicts at the factory’s designated smoking area.

Twenty-five years after companies began banning smoking in the workplace, the increasing popularity of e-cigarettes is forcing them to review their policies.

Many corporations still ban “vaping” as they wait to see if the FDA will regulate e-cigarettes as strictly as regular smokes. Yet Kraft and Walgreen allow local managers to set the rules. Smaller firms, especially creative agencies and Web startups, have already adopted a more laissez-faire attitude.

US e-cigarettes sales will triple this year to $1.5 billion, according to Euromonitor International. They’re expected to accelerate as traditional tobacco makers muscle into a market previously dominated by small players.

Both Altria Group and Reynolds American, the biggest US tobacco sellers, are expanding distribution of e-cigarettes. Lorillard controls about half of the USmarket with blu eCigs, which it acquired last year.

So far, small companies where bosses can monitor whether e-cigarettes bother co-workers are more likely to allow vaping.

“It is all new to us,” said Ged King, president of the Sales Factory, a 35-employee marketing firm based here. He looked up in surprise during a staff meeting a few months ago to see an employee vaping. Now several employees do it, presumably “to help them kick the smoking habit,” he said.

“We’ve not put a policy in place because nobody has complained,” King said.

The technology gives users seeking anonymity an edge. E-cigarettes heat liquid nicotine into an inhaled vapor, dissipating faster than cigarette smoke. So workers more worried about being seen than smelled puff e-cigarettes in empty offices and bathrooms, according to posts on the E-Cigarette Forum website, where visitors share favorite flavors and vaping lounges, plus tips on how to avoid offending co-workers.

“I’m doing it on the down-low and just close the door,” said Dennis Rumpf, a construction manager in Charlotte, N.C. He declined to identify his employer because it didn’t authorize him to speak publicly.

Rumpf, 37, said he alternates between menthol and classic tobacco flavors in the e-cigarettes he’s been using for six months, after 19 years as a smoker.

“I have people come into my office all the time and I’m sure they’d say something if they noticed anything,” he said.

Web developer Adam Gray has won his boss’s approval to use e-cigarettes at his Minnetonka, Minnesota, office.

“It makes him more productive and sets him on a path for better health,” said Paul Hanson, chief operating officer of TrackIF LLC, a firm that monitors price changes across the Web.

Gray, 27, can “vape all day, a puff here and there” without leaving his desk, he said.

Kraft doesn’t have a companywide e-cigarettes policy and allows managers to make their own rules as long as they abide by local and state laws. Walgreen, the largest US drugstore retailer, also leaves decisions to office managers.

However, health and regulatory uncertainties have prompted many employers to treat e-cigarettes like regular cigarettes, said Paula Andersen, a registered nurse at Buck Consultants, a human- resources firm that advises companies on health programs.

“We recommend that if companies do have a tobacco-free policy that they call electronic cigarettes out as well,” said Andersen, who declined to identify clients.

Exxon Mobil and General Motors allow vaping in designated smoking areas, while CVS Caremark and Lowe’s ban e-cigarettes and regular smokes. Levi Strauss & Co. forces vapers to go outside.

“For the most part, people who vape are treated as smokers,” said LeeAnn Blohm, who favors chocolate peanut butter and butterscotch e-cigarettes. She declined to identify her employer in Austin, Texas, which doesn’t allow vaping inside.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 27,2020

After admitting that the world may have a COVID-19 vaccine within one year or even a few months earlier, the World Health Organisation (WHO) on Friday said that UK-based AstraZeneca is leading the vaccine race while US-based pharmaceutical major Moderna is not far behind.

WHO Chief Scientist Soumya Swaminathan stated that the AstraZeneca's coronavirus vaccine candidate is the most advanced vaccine currently in terms of development.

"I think AstraZeneca certainly has a more global scope at the moment in terms of where they are doing and planning their vaccine trials," she told the media.

AstraZeneca's Covid-19 vaccine candidate developed by researchers from the Oxford University will likely provide protection against the disease for one year, the British drug maker's CEO told Belgian radio station Bel RTL this month.

The Oxford University last month announced the start of a Phase II/III UK trial of the vaccine, named AZD1222 (formerly known as ChAdOx1 nCoV-19), in about 10,000 adult volunteers. Other late-stage trials are due to begin in a number of countries.

Last week, Swaminathan had said that nearly 2 billion doses of the COVID-19 vaccine would be ready by the end of next year.

Addressing the media from Geneva, she said that "at the moment, we do not have a proven vaccine but if we are lucky, there will be one or two successful candidates before the end of this year" and 2 billion doses by the end of next year.

Scientists predict that the world may have a COVID-19 vaccine within one year or even a few months earlier, said the Director-General of the World Health Organization even as he underlined the importance of global cooperation to develop, manufacture and distribute the vaccines.

However, making the vaccine available and distributing it to all will be a challenge and will require political will, WHO chief Tedros Adhanom Ghebreyesus said on Thursday during a meeting with the European Parliament's Committee for Environment, Public Health and Food Safety.

One option would be to give the vaccine only to those who are most vulnerable to the virus.

There are currently over 100 COVID-19 vaccine candidates in various stages of development.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 4,2020

The Union health ministry on Friday revised the dosage of anti-viral drug remdesivir to be administered to coronavirus patients in the moderate stage of illness from the earlier six days to five days as it issued an updated 'Clinical Management Protocols for COVID-19'.

The drug, administered in the form of injection, should be given at a dose of 200 mg on day one followed by 100 mg daily for four days (total five days), the new treatment protocols stated.

The Health Ministry on June 13 had allowed the use of remdesivir for restricted emergency use in moderate cases under "investigational therapies".

"Under emergency use authorisation, remdesivir may be considered for patients in moderate stage requiring oxygen support," the document stated.

It is not recommended for those with severe renal impairment and high level of liver enzymes, pregnant and lactating women, and those below 12 years, it said.

The ministry also okayed off-label application of tocilizumab, a drug that modifies the immune system or its functioning, and convalescent plasma for treating COVID-19 patients in the moderate stage of illness as "investigational therapies".

It also recommended hydroxychloroquine for patients during the early course of the disease and not for critically-ill patients.

On June 27, the ministry had included an inexpensive, widely used steroid dexamethasone in treatment protocols for COVID-19 patients in the moderate to severe stages of their illness among other therapeutic measures.

The ministry advised use of dexamethasone, which is already used in a wide range of conditions for its anti-inflammatory and immunosuppressant effects, as an alternative choice to methylprednisolone for managing moderate to severe cases of coronavirus infection.

India's COVID-19 cases soared by over 20,000 in a day for the first time taking the country's total tally to 6,25,544 on Friday while the death toll climbed to 18,213 with 379 new fatalities, according to the Union Health Ministry data updated at 8 am.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 11,2020

The World Health Organisation (WHO) Director-General Tedros Adhanom Ghebreyesus said that more research needs to be done to better understand the extent to which COVID-19 is being spread by people who don't show symptoms.

"Since early February, we have said that asymptomatic people can transmit COVID-19, but that we need more research to establish the extent of asymptomatic transmission," the WHO chief said at a virtual press conference from Geneva on Wednesday, Xinhua news agency reported.

"That research is ongoing, and we're seeing more and more research being done," he added.

Saying that the world has been achieving a lot in knowing the new virus, the WHO chief told reporters that "there's still a lot we don't

"WHO's advice will continue to evolve as new information becomes available," he said.

Tedros stressed that the most critical way to stop transmission is to find, isolate and test people with symptoms, and trace and quarantine their contacts.

"Many countries have succeeded in suppressing transmission and controlling the virus doing exactly this," Tedros said.

Meanwhile, Michael Ryan, executive director of WHO Health Emergencies Program, said Wednesday that the COVID-19 pandemic is still evolving.

"If we look at the numbers... this pandemic is still evolving. It is growing in many parts of the world," he said. "We have deep concerns that health systems of some countries are struggling, under a huge strain and require our support, our help and our solidarity."

He said "each and every country has a different combination of risks and opportunities, and it's really down to national authorities to carefully consider where they are in the pandemic."

In Europe, the risk issue now are about travels and the opening of the schools, around risk management, mass gathering, surveillance and contact tracing, said the WHO official.

In Southeast Asian countries, where to a great extent transmissions have been under control, governments are more concerned about the re-emergence of clusters, while in South America, the issue of PPE for health workers has not gone away, said Ryan.

As regards Africa, Ryan said the death rates have been very low in the past week, but the health system can be overwhelmed, as it would have to cope with other diseases such as malaria.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.